7-[(R)-1-hydroxy-4-methylpentan-2-ylamino]-5-mercaptothiazolo[4,5-d]pyrimidin-2(3H)-one | 1189040-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 7-[(R)-1-hydroxy-4-methylpentan-2-ylamino]-5-mercaptothiazolo[4,5-d]pyrimidin-2(3H)-one
• 英文别名: 7-[[(2R)-1-hydroxy-4-methylpentan-2-yl]amino]-5-sulfanylidene-3,4-dihydro-[1,3]thiazolo[4,5-d]pyrimidin-2-one
• CAS: 1189040-15-0
• 化学式: C₁₁H₁₆N₄O₂S₂
• 分子量: 300.406
• InChiKey: REYBEAHIGKTXTE-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  143
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-[(R)-1-hydroxy-4-methylpentan-2-ylamino]-5-mercaptothiazolo[4,5-d]pyrimidin-2(3H)-one 、 2-(1-chloroethyl)pyridine, monohydrochloride 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以28%的产率得到7-[(R)-1-hydroxy-4-methylpentan-2-ylamino]-5-[1-(pyridin-2-yl)ethylthio]thiazolo[4,5-d]pyrimidin-2(3H)-one
  参考文献：
  名称：

  US2009/247555

  摘要：

  公开号：
• 作为产物：
  描述：

  7-{[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino}-5-[(1-phenylethyl)thio][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 反应 4.83h， 以89%的产率得到7-[(R)-1-hydroxy-4-methylpentan-2-ylamino]-5-mercaptothiazolo[4,5-d]pyrimidin-2(3H)-one
  参考文献：
  名称：

  US2009/247555

  摘要：

  公开号：

文献信息

• 5,7-Disubstituted[1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 258
  申请人：Dahlstrom Mikael

  公开号：US20090247555A1

  公开（公告）日：2009-10-01

  There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX 3 CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, is pulmonary diseases such as COPD, asthma or pain.

  本发明揭示了新型的5,7-二取代[1,3]噻唑并[4,5-d]嘧啶-2(3H)-酮衍生物(I)的公式，其中R1、R2、R3、R4、R5、R6和R7如规范中所定义，以及其药学上可接受的盐，以及它们的制备方法，包括它们在治疗中的药物组合物和使用。公式(I)化合物是CX3CR1受体拮抗剂，因此在治疗或预防神经退行性疾病、脱髓鞘性疾病、心血管和脑血管动脉粥样硬化性疾病、周围动脉疾病、类风湿性关节炎、肺部疾病如COPD、哮喘或疼痛中特别有用。
• [EN] NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES 258<br/>[FR] NOUVEAUX DÉRIVÉS 258 DE [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE 5,7-DISUBSTITUÉS
  申请人：ASTRAZENECA AB

  公开号：WO2009120140A1

  公开（公告）日：2009-10-01

  There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.